PARTNER Is Looking for a Project

PARTNER SEARCH

7TH. EU FRAMEWORK PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION (2007-2013)

PARTNER is looking for a Project

1.) PARTNER OFFERED Organisation Instituto Neofacial Type of organisation SME, (IND, SME, RES, HE, RES others) Contact person Jose C. Moreno MD, PhD Email [email protected] Telephone 0034 924 22 97 77 Postcode, city 06010 Badajoz Country Spain Website www.neofacial.com

Role in desired project technology research : x training : x development : dissemination : demonstration : x other : Expertise offered and what I Minimally invasive computer aided surgery techniques would like to do validation in oral implantology and orthognatic surgery.

I am familiar with the European Framework Programme :

YES x NO Familiar but not participant yet

2.) COORDINATOR / PROJECT sought after (for proposal submission only)

WP topic : Project type Large scale integrating collaborative project Small or medium-scale focussed research project Collaborative projects targeted to SMEs CA or SSA Network of Excellence

Keywords of project:

I AGREE WITH THE PUBLICATION OF MY DATA

PLEASE FILL IN THE PROFILE FORM AND RETURN IT TO:

PARTNER SEARCH

Dear colleagues,

Please, find attached partner search for the topic KBBE-2007-3-2-08 BIO- INFORMATICS - Microbial genomics and and bio-informatics.

I would appreciate if you could distribute this partner search among your clients.

Thank you very much for your collaboration

With best regards

Dace Tirzite

Latvian NCP for 7th FP priority "Food, Agriculture, Fisheries and Biotechnology" Ministry of Education and Science, Valnu str.2, Riga LV-1050

Tel: +371-7047963,

e-mail: [email protected]

PARTNER SEARCH FORM

INFORMATION OF ORGANIZATION Name of organization Institute of Microbiology and Biotechnology University of Latvia X Organization type Research Education Industry Technology Transfer

Consultancy Other Organization Size (employees) < 10 10-49 X 50-99 100-199 200-249 >250

Short description of LU MBI is the research institute founded as a structural unit of the organization University of Latvia in 1993 on the basis of the August Kirchenstein (main research activities) Institute of Microbiology at the Academy of Sciences of Latvia. LU MBI consists of 10 laboratories carrying out research projects in microbiology, biotechnology and environmental protection. Academic staff represents researchers (25 Dr. sc. and Dr. habil. sc.) in the fields of microbiology, biochemistry, engineering etc. Main research activities: - physiology, biochemistry and genetics of microorganisms- producers of amino acids, enzymes, biopolymers etc.; - microbial cytology and metabolism regulation under extreme environment (ksero- and osmotolerance); - environmental microbiology, food and fuel biotechnology, including bioconversion of agricultural raw materials; - bioengineering (modeling and optimization for hydrodynamic parameters of bioreactors). LU MBI has experience to participate in EC Framework programmes. PROJECT DETAILS Project type X Other: Collaborative research NoE CA SSA Topic KBBE-2007-3-2-08: BIO-INFORMATICS - Microbial genomics and bio-informatics. Title Topology and compositional determinants of secretion signals as potent classifiers for non-classically secreted proteins. Description Background information Increasing amount of large scale date from genomic research determines urgent need to specify the proteome, including the secretome, i.e., the part of proteins secreted form the cell. Capability of bacteria to release particular proteins into the extracellular medium by means of different secretion pathways are processes of basic importance for bacterial life as well as provides diverse biotechnological applications. A number of prediction and classification tools have been developed to predict adequate protein cell localization and signal peptide cleavage sites in proteins secreted by ‘classical’, i.e., signal peptide - dependent pathways. However approximately 25 per cents of known extracellular proteins are classified as ‘non-classically’ secreted proteins lacking cleavable signal peptides. At present only one prediction method Secretome P can be used for this purpose [1, 2], which nevertheless does not specify any definite secretion type (type III or type I) possibly involved in non-classical protein secretion. Several compositional and structural features at the termini of sequences have been proposed as specific unprocessed secretion signals of ‘non-classically’ secreted proteins. However, definite sizes, location and composition of secretion signals remain obscure, possibly due to the fact that studies in the field are mostly focused on some functionally related protein groups from a limited number of organisms and, as a consequence, fundamentals of secretion processes remain to be elucidated and fully understood. Objectives and expected results Our recent studies revealed definite amino acid frequencies of occurrence [3] and selected variables from periodicity patterns of aromatic and aliphatic amino acid residues [4] as the reliable predictors to discriminate between type III and type I secreted proteins, however further investigations in the field could provide substantially stronger set of predictors. The goal of this research project is to define more precisely the composition, size and location of possible secretion signal for substrates of ‘non-classical’ secretion (type III and type I) pathways to provide strongly improved tool for identification of secretome proteins from genomic sequences of bacteria (proteobacteria and, possibly, firmicutes [4]). The tool for identification and classification of secretome proteins could verify the compatibility between various secretion substrates (recombinant heterologous proteins such as vaccines, etc.) and secretion machinery (of potent carrier strain) in order to predict overall efficiency of the process. Achieved prediction and classification algorithms could provide a basis for implementation of prediction and classification tool. Basic references [1] J.D. Bendtsen, L. Kiemer, A. Fansbøll and S. Brunak: “Non-classical protein secretion in bacteria”, BMC Microbiology, (2005), 5:58. [2] J.D. Bendtsen, L.J. Jensen, N. Blom, G. von Heijne and S. Brunak: “Feature-based prediction of non-classical and leaderless protein secretion”, Protein Eng. Des. Sel., Vol. 17, (2004), pp. 349-356. [3] P. Zikmanis, I. Andersone, M. Baltkalne: “Discriminative features of type III and type I secreted proteins from Gram-negative bacteria.”- CEJB, (2006), 1(1): 124-136. [4]I. Andersone, P. Zikmanis: “Distinctive amino acid residue periodicities in terminal sequences of type III and type I secreted proteins from proteobacteria.”- CEJB, (2007), 2(2): 192-205. Partners already involved

Target partner(s) BIO-INFORMATICS - Microbial genomics and bio- (type, expertise required and informatics Call: KBBE-2007-2A role in the project) (Research organizations interested in Protein subcellular location prediction, Microbial proteomics or Software development)

CONTACT DETAILS Name, Surname: Dr.habil.biol. Peteris, Zikmanis; Inara, Andersone; Ieva, Minicha Address: Kronvalda Boulevard 4, LV-1586, Riga, Latvia. Phone: +371 7033898 Fax: +371 7034885 e-mail: [email protected]*, [email protected], [email protected] Web site:

Dear Sir / Madam,

The Hellenic Biotech Association is happy to support the following research, conducted by BIONOVA Ltd. – Health & BIO NCP for Greece – and HELEXPO S.A. – the biggest Congress organiser in South-eastern Europe, on participation to event on subject of Biosciences and Biotechnology.

You are kindly requested to forward this communication to your members.

At your disposal for any further inquiries.

Hellenic Biotech Association

Evangelos Bonoris, MBA, D.I.C. Managing Director BIONOVA Ltd

EuropaBio Board Member

NCP Coordinator for "Health" & "Bio"

Solomou & Stamatas 5A

GR-14 575, Stamata (Drossia)

phone: (+30) 210.800.49.10

fax: (+30) 210.800.49.13

www.bionova.gr / www.ncp-bionova.gr

[email protected]

21st Century Bio-Science Markets and Innovations”, Athens 2008

The biggest bio-business partnership and innovation exhibition in South Eastern Europe

GLOBAL RESEARCH ON PARTICIPATION TO EVENT ON SUBJECT OF BIOSCIENCES & BIOTECHNOLOGY

Dear Ladies and Sirs,

All over South Eastern Europe and the Mediterranean we are witnessing a rising wave of technological and innovation evolution in the fields of bio and life sciences. Many global economy experts and financial analysts see the region as a new center of economic development and a hub of successful commercial and R&D alliances.

Greece and the city of Athens, the economic centre of the Balkans, are willing to play a significant role in this development.

Therefore to best promote innovative research and successful international alliances, BIONOVA, the leading biotech and bioscience consulting firm in Greece, the founder of Hellenic Biotech Association, the organizer of the annual IGBF (International Greek biotech Forum), the National Contact Point for Health and Bio of the 7th European Framework Program and a member of the Governing Board of EuropaBio, in cooperation with Helexpo is planning to organize in 2008 in Athens the first International Exhibition of Biotechnological and life science products, services and business partnerships under the title “21st Century Bio-Science Markets and Innovations. The current research aims to accentuate the special needs of the potential participants and guests and to prepare a pioneering presentation of innovative biotechnology products.

We would like to reassure you that your answers will remain absolutely confidential and will be presented in the form of statistical tables only.

The questionnaire consists of 16 multiple choice questions that will take less than 8 minutes.

Each inbound questionnaire will receive its own four digit code and following a draw, 6 months prior to the conduct of the exhibit the winner will win a free participation booth.

Thank you in advance for your participation,

Dear All,

Please find attached a Romanian partner profile willing to participate in the following topic: Health 2007- 2.4.2-5: Cell therapies for the treatment of heart ischemia

I would appreciate it very much if you could disseminate their profile forms to relevant researchers in your country.

Thanks in advance for your help and collaboration.

Best regards,

Ph D Olguta Iordache

Counselor

HEALTH - NCP - FP 7

National Authority for Scientific Research

Ministry of Education, Research and Youth

21-25 Mendeleev Str., District 1

010362, Bucharest, ROMANIA

Tel: +40 21 319 23 25/129;

+40 21 319 23 26/129; +40 21 319 23 27/129;

Fax +40 21 318 30 60

E-mail: [email protected]

Date 2007 06 26 Deadline yyyy mm dd

CONTACT SANDESC DOREL MD, Ph D

Organisation Emergency County Hospital Department Anesthesioloy and Intensive Timisoara Care Unit Contact person SANDESC DOREL MD, Ph D Male/female Male Address I. Bulbuca st No 156 Email [email protected] Postcode 300736 Fax +40256486956 City Timisoara Telephone +40748331113 Country Roumania Website www.hosptm.ro

Are you familiar with the European Framework Programme?

YES x NO

PROJECT

Project type x Large Collaborative x Network of x Small Collaborative Other: Project Excellence Project Status x planned for running EU project submission Call references

Priorities’ Main Optimising cardiac cell preparation for use in transplantation Research Areas studies. Evaluate the complexity of intracellular signalling pathways involved in ischemic and anesthetic induced postconditioning using a rat experimental model for regional ischemia-reperfusion (I/R), respectively to assess the activation sequence of different mediators in order to elucidate the cardioprotective mechanisms. Volatile anesthetics produce powerful cardioprotection in both experimental animal models of ischemia – reperfusion injury and human myocardium comparable to that elicited by ischemic preconditioning (IPC), the most powerful phenomenon of endogenous protection. Cardioprotection by postconditioning has apparently a similar signal transduction as preconditioning but has the advantage of applying it at reperfusion in clinical settings. The objectives are: (1) assessment of ischemic and anesthetic postconditioning protocols, which confer maximum cardioprotection against necrotic/apoptotic cell death, (2) systematic study of cardioprotection induced by both phenomenon in order to identify a possible cumulative effect, (3) evaluation of the role of various kinases involved in the protective RISK pathway and their place in the protective sequence through molecular biology studies, (4) investigation of a possible cumulative protection conferred by the association of anesthetic postconditioning with different protocols of ischemic postconditioning. Our department has higlly qualified and experienced personel in research on the experimental rats and development of various technics for a experimental animal models of ischemia – reperfusion injury and anesthetic and ischemic pre/postconditioning. Workprogramme FP7, FP7 IDEAS, FP7 COOPERATION, FP7 HEALTH Topic HEALTH-2007-2.4.2-5 Project description Evaluate the complexity of intracellular signaling pathways involved in ischemic and anesthetic induced pre/postconditioning using a rat experimental model for regional ischemia-reperfusion (I/R), respectively to assess the activation sequence of different mediators in order to elucidate the cardioprotective mechanisms

Keywords Transplantation studies, rats models, preconditioning, postconditioning, ischemic, anesthetic. Partners already involved Project budget (for Budget reserved for the running SMEs projects)

Profile of Partner sought

Role x technology development x research x training

x dissemination demonstration other: Country /region

Start of x start-up phase x mid-term end-phase partnership Expertise required - ischemic preconditioning - ischemic postconditioning - advanced molecular biology for kinases involved in intracellular signaling pathways - analyses of mithocondrial O2 consumption. PARTNER is looking for a Project

1.) PARTNER OFFERED Organisation Hermex Type of organisation RES (IND, SME, RES, HE, others) Contact person Daniel Fernández-Bergés Email [email protected] Telephone 34629619820 Postcode, city 06700 Country Spain Website

Role in desired project technology research : YES training : development : dissemination : demonstration : other : Expertise offered and what I Expertise in research about cardiovascular diseases, would like to do inflammation markers, gender in myocardial infarction, cardiovascular risk factors. We would like join another European groups interesting in population based studies in cardiovascular risk factors

WP topic : Cardiovascular risk factors, inflammation markers, genomics in cardiovascular diseases

Project type Large scale integrating collaborative YES project Small or medium-scale focussed research project Collaborative projects targeted to SMEs CA or SSA Network of Excellence

Keywords of project: Cardiovascular risk factors, epidemiology, inflammation markers, genomics in cardiovascular diseases.

PARTNER SEARCH

7TH. EU FRAMEWORK PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION (2007- 2013)

1.) PARTNER OFFERED Organisation SISTEMAS GENÓMICOS S.L. Type of organisation SME (IND, SME, RES, HE, others) Contact person David Garcia Email [email protected] Telephone 902364669 Postcode, city 46980 Paterna Country SPAIN Website www.sistemasgenomicos.com

Role in desired project technology research : X training : X development : X dissemination : demonstration : other : X X Expertise offered and what I Sistemas Genómicos SL is a biotech company would like to do specialised in genetic testing and genome research. The company is the largest privately owned organisation providing DNA analysis in Spain and the only one that has taken part in international genome sequencing projects. Our works in the biomedical field include diagnosis of genetic diseases, rare disease and preimplantation genetic diagnosis. Nowadays we are carrying out the project: “New therapeutic approaches for myotonic dystrophy: functional genomics and in vivo drug discovery studies”, aiming to discover new therapeutic targets in dystrophia miotonica. In addition we are part of the Tomato Genome Sequencing Consortium. We offer our expertise in genome sequencing and RT-PCR analyses to any project related to molecular biology.

I am familiar with the European Framework Programme:

YES X NO

WP topic : HEALTH-2007-1.4-6

Project type Large scale integrating collaborative X project Small or medium-scale focussed research X project Collaborative projects targeted to SMEs X CA or SSA X Network of Excellence

Keywords of project: Molecular biology, biotechnology, cancer, oncology, rare diseases, genetic diseases, PGD, sequencing, RT-PCR, dystrophia, allergen, GMO, product authentification,

I AGREE WITH THE PUBLICATION OF MY DATA PLEASE FILL IN THE PROFILE FORM AND RETURN IT TO: [email protected]

PARTNER SEARCH

1.) PARTNER OFFERED Organisation FUNDACIÓN GAIKER Type of organisation RTD (IND, SME, RES, HE, others) Contact person EMELINE POSTIGO Email [email protected] Telephone (0034) 94-600-23-23 Postcode, city 48190 Country SPAIN Website WWW.GAIKER.ES

Role in desired project technology research : x training : development : dissemination : demonstration : other : Expertise offered and what I Proteomics, diagnostic. would like to do

YES NO

WP topic : 2.3.1-1: Novel targets for drugs against Gram negative bacteria.

Project type Large scale integrating collaborative project Small or medium-scale focussed research x project Collaborative projects targeted to SMEs CA or SSA Network of Excellence

Keywords of project: Gram bacteria. Diagnostic.

PARTNER SEARCH

1.) PARTNER OFFERED Organisation FUNDACIÓN GAIKER Type of organisation RTD (IND, SME, RES, HE, others) Contact person EMELINE POSTIGO Email [email protected] Telephone (0034) 94-600-23-23 Postcode, city 48190 Country SPAIN Website WWW.GAIKER.ES

Role in desired project technology research : x training : development : dissemination : demonstration : other : Expertise offered and what I Proteomics, diagnostic. would like to do I am familiar with the European Framework Programme :

YES NO

WP topic : 2.3.1-1: Novel targets for drugs against Gram negative bacteria.

Project type Large scale integrating collaborative project Small or medium-scale focussed research x project Collaborative projects targeted to SMEs CA or SSA Network of Excellence

Keywords of project: Gram bacteria. Diagnostic.

Dear All,

An Egyptian research group is interested to join an already formed consortium if available or finding EU coordinator and partners to submit a proposal under the following topic:

- HEALTH-2007-1.4-6: Innovative therapeutic approaches and interventions, stem cell lines for cell based therapies.

I would appreciate it if you could disseminate this Consortium search amongst potential researchers/organizations in your countries.

Thank you and best regards,

Zeinab El-Sadr EU Funded Research Project Partner Search Form

Date: 3/6/2007 Deadline:18 September 2007

Contact

Organization Cairo University Pediatric Department Diabetes Endocrine Hospitals Metabolism Pediatric Unit

Contact person Ghada Mohamad Anwar, associate professor of pediatrics, Cairo University.

Email [email protected] [email protected]

Address 94, khatem elmorsaleen street, Haram, Giza.

Postcode City Cairo

Country Egypt

Telephone 20122196024 Fax 20223657505 2025644829

Website www.aboulreesh.eg.net Familiar with the European Framework Programme?  YES  NO

PROJECT

Title: high throughput molecular diagnostics in individual patients for genetic diseases with heterogeneous clinical Acronym: presentation. PARTNER SEARCH

7TH. EU FRAMEWORK PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION (2007- 2013)

1.) PARTNER OFFERED Organisation SISTEMAS GENÓMICOS S.L. Type of organisation SME (IND, SME, RES, HE, others) Contact person David Garcia Email [email protected] Telephone 902364669 Postcode, city 46980 Paterna Country SPAIN Website www.sistemasgenomicos.com

Role in desired project technology research : X training : X development : X dissemination : demonstration : other : X X Expertise offered and what I Sistemas Genómicos SL is a biotech company would like to do specialised in genetic testing and genome research. The company is the largest privately owned organisation providing DNA analysis in Spain and the only one that has taken part in international genome sequencing projects. Our works in the biomedical field include diagnosis of genetic diseases, rare disease and preimplantation genetic diagnosis. Nowadays we are carrying out the project: “New therapeutic approaches for myotonic dystrophy: functional genomics and in vivo drug discovery studies”, aiming to discover new therapeutic targets in dystrophia miotonica. In addition we are part of the Tomato Genome Sequencing Consortium. We offer our expertise in genome sequencing and RT-PCR analyses to any project related to molecular biology.

I am familiar with the European Framework Programme:

YES X NO

WP topic : HEALTH-2007-1.2-6

Project type Large scale integrating collaborative X project Small or medium-scale focussed research X project Collaborative projects targeted to SMEs X CA or SSA X Network of Excellence

Keywords of project: Molecular biology, biotechnology, cancer, oncology, rare diseases, genetic diseases, PGD, sequencing, RT-PCR, dystrophia, allergen, GMO, product authentification,

PLEASE FILL IN THE PROFILE FORM AND RETURN IT TO: [email protected]

Project type  Large-scale integrating  Small or medium-scale focused collaborative project research collaborative project  Targeted to SMEs  Network of Excellence  Coordination and Support Research for the benefit Action of SMEs  Other (Marie Curie Actions, ERA-NET…) Status  Planned for submission

Call references  2 nd Call

Priorities’ Main HEALTH-2007-1.2-6: High throughput molecular diagnostics in Research Areas individual patients for genetic diseases with heterogeneous clinical (Topics from presentation. Workprogramme)

Keywords Congenital adrenal hyperplasia, genital ambiguity, 21 hydroxylase deficiency.

Previous  Genetic studies in congenital adrenal hyperplasia due to 21 publications of the hydroxylase deficiency in Egyptian patients. Isis Ghaly, Fatma El team Mougy, Mona El Taggy & Mona Hafez. Journal of Arab Child 8(4), Dec 1997.

 Late onset congenital adrenal hyperplasia in Egyptian girls. Mona Hafez, Isis Ghaly, Nermine Salah, shereen Abd El Ghaffar & Lubna Fawaz. Hormone research 51(2),1999.

 Prevalence of late onset congenital adrenal hyperplasia in 100 Egyptian women diagnosed as polycystic ovarian syndrome. Mohamed Shereen, Fayza Abd El Hamid & Mona Hafez. British journal of Obstetric & Gynecology 105 (17) 1998

 Late onset congenital adrenal hyperplasia in Egyptian patients; clinical presentation, hormonal profile, molecular diagnosis and response to therapy. Mona Hafez, Lamia Mansour & Jean Fiete. The Journal of Arab Child 11(1), March 2000

 Congenital adrenal hyperplasia is still underdiagnosed. The need for routine neonatal screening. Mona Hafez, Nermine Salah, Isis Ghaly, , Fatma El Mougy & Shereen Abd El Ghaffar. The Gazette of Egyptian Pediatric association Journal of Arab Child 11(3), Sep 2000

Role of the team seeking partner: 1. collection and diagnosis of cases 2. addressing the clinical presentation 3. performing the hormonal profile of the cases 4. collection of the blood samples for DNA analysis 5. follow up of the cases

Profile of Partner Sought

Role    technology development research training    dissemination demonstration other If another role expected, please specify it here Coordinator/Partners

Country /region Egypt – Cairo

Start of    partnership start-up phase mid-term end-phase

Expertise DNA technology expertise required

I agree with the publication of my data Please fill-in and return it to: Egyptian National Scientific & Technical Information Network (ENSTINET) By email to: [email protected] By fax. To: (+202) 7947807

EU Funded Research Project Partner Search Form

Date: 29/4/2007 Deadline: 18 September 2007

Contact

Organization Faculty of Medicine, Departments Cairo University Medical Biochemistry Department

Contact Professor Dr. Hanan H. Fouad person

Email [email protected]

Address POB 31, Manial El-Roda mail, mail code 11553, Cairo , Egypt

Postcode 11553 City Cairo Cairo

Country EGYPT

Telephone +2010 4885380 Fax +202 5280534

Familiar with the European Framework Programme? √ YES  NO

PROJECT

Title: Stem Cells Differentiation for Age-Associated Erectile Acronym: Dysfunction, and infertility: Preclinical and clinical trials of Use of Stem Cell differentiation into hematopoietic, mesenchymal stem cells and spermatogonial stem cavernous tissue and cells with different escalating doses. spermatozoa

Project type Large-scale integrating Small or medium-scale focused √ collaborative project research collaborative project Targeted to SMEs Network of Excellence Coordination and Support Research for the benefit Action of SMEs Other (Marie Curie Actions, ERA-NET…)

Status √ Planned for submission Call references √ 2nd Call

Priorities’ Main Call: FP7-HEALTH-2007-B Research Areas (Topics from Workprogramme) HEALTH-2007-B - 1.4-6 : Innovative therapeutic approaches and interventions, stem cell lines for cell based therapies.

Idea of the Project Purpose is to develop new knowledge, new technology, new products (stem cells) through research activities. Two studies will be conducted using Hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) for ED and the use of spermatogonial stem cells for male infertility due to defective spermatogenesis.

First study for the treatment of ED involves the use of mesenchymal stem cells (MSCs) or hematopoietic stem cells (HSCs) that can be easily isolated, readily ex vivo expanded and efficiently differentiated into penile cells expressing endothelial and smooth muscle cell markers (Trinity et al., 2006) .

As regards HSCs, Tian et al., (2006) proved the therapeutic value of HSCs in vascular reconstruction and functional restoration of vascular endothelial cells in experimental diabetic retinopathy. Furthermore, Li et al., (2006) reported the therapeutic efficacy of mononuclear cells (CD34+) mobilized into peripheral blood in human cases of limb ischemia through angiogenesis and upregulation of angiogenic factors. No previous studies conducted on the use of HSCs for erectile dysfunction (ED), but it is evident that restoration of vascular endothelial function may be of value for ED subjects of vascular causes.

The present study will be conducted in TWO STAGES: The 1st stage is an experimental phase that will be carried on to improve the technology of isolation of both MSCs and HSCs, propagation of stem cells in culture and investigate the efficacy of intracavernous administration of MSCs or HSCs in rats. Comparison between MSCs and HSCs as regards therapeutic efficacy, different stem cell dosage schedules and any side effects will be addressed.

The 2nd stage is a clinical trial phase that will be conducted on aged men with vascular erectile dysfunction. Isolation of either HSCs or MSCs from patient own bone marrow, propagation, identification and intracavernous administration will be tried.

The following parameters will be evaluated:

1. Evaluation of erectile function by physiological assessment of cavernous smooth muscle tone. 2. Immunostaining for some endothelial and smooth muscle cell markers such as anti-smooth muscle myosin heavy chain. 3. Western blot analysis for eNOS and HO-1 4. Constitutive NOS activity and heme oxygenase activity. 5. cGMP levels in cavernous tissue. 6. Histopathological examination to detect the degree of vascular dilatation of the cavernous tissue and any evidence of toxic or inflammatory reactions.

The 2nd study involves an innovatie approach for treatment of male infertility involves the use of spermatogonial stem cell (SSC) isolated from the donor mice testis, propagation then injection into the testis of the recipient mice. A transplantation assay was developed for the mouse in which SSC are introduced into the seminiferous tubules of a recipient mouse, and spermatogonial stem cell (SSC) activity is identified by the development of colonies of spermatogenesis in the recipient testes, with each colony representing the clonal expansion of an individual stem cell (Ralph et al., 1994).

Keywords Ageing, stem cell, erectile dysfunction, infertility

Commitment/Work - The research team is experienced in erectile dysfunction topic at the to be offered molecular level specially related to the usage of gene therapy and gene induction or inhibition for management of erectile dysfunction. - The research team is also experienced in isolating mesenchymal stem cell from long bones of rats and differentiating them into beta cell of pancreas and also into liver cells.

S&T Publications of - Adult Human Bone Marrow- Derived Stem Cells Differentiate into the team related to Insulin- secreting Cells in Vitro. This paper has been presented in the topic International Congress in Morroco, Marrakech, 1-3- Mars 2007, 15eme CONGRESS SOCIETE MAROCAINE, DE CANCEROLOGIE

- Abdel Aziz MT, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, Ahmed HH, Rashed LA, Sabry D, Hassouna AA, Hasan NM. Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem. 2007 May 3; [Epub ahead of print] This paper has been presented in International Congress in Morroco, Marrakech, 1-3- Mars 2007, 15eme CONGRESS SOCIETE MAROCAINE, DE CANCEROLOGIE

Profile of Partner Sought

Role √ technology development √ research training

dissemination demonstration other If another role expected, please specify it here Coordinator/Partners

Country /region EGYPT CAIRO

Start of partnership √ start-up phase mid-term end-phase

Expertise Experience in stem cell (MSCs – HSCs) identification and differentiation required I agree with the publication of my data Please fill-in and return it to: Egyptian National Scientific & Technical Information Network (ENSTINET) Egypt National Contact Point for Health By email to: [email protected] By fax. To: (+202) 7947807

or 7964421 Fax.: (+202) 7947807 Cel.: (+2)012 997 998 2 e-mail: [email protected] URL: http://www.sti.sci.eg